Neurodegenerative disorders and nanoformulated drug development

Department of Pharmacology & Experimental Neuroscience, Center for Neurovirology & Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE 68198-5880, USA.
Nanomedicine (Impact Factor: 5.41). 08/2009; 4(5):541-55. DOI: 10.2217/nnm.09.37
Source: PubMed


Degenerative and inflammatory diseases of the CNS include, but are not limited to, Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis and HIV-1-associated neurocognitive disorders. These are common, debilitating and, unfortunately, hold few therapeutic options. In recent years, the application of nanotechnologies as commonly used or developing medicines has served to improve pharmacokinetics and drug delivery specifically to CNS-diseased areas. In addition, nanomedical advances are leading to therapies that target CNS pathobiology and as such, can interrupt disordered protein aggregation, deliver functional neuroprotective proteins and alter the oxidant state of affected neural tissues. This article focuses on the pathobiology of common neurodegenerative disorders with a view towards how nanomedicine may be used to improve the clinical course of neurodegenerative disorders.

Download full-text


Available from: Lisa M Kosloski, Oct 07, 2015
25 Reads
  • Source
    • "Dementia is the primary clinical symptom noticed, along with impaired learning and cognition. As the disease progresses, irritability, confusion, and behavioral changes may persist.5,21,22 The brains of patients with Alzheimer’s disease show a characteristic pattern of β-amyloid (Aβ) plaques and neurofibrillary tangles that are considered to be the pathological hallmarks of the disease and progression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We are now in an aging population, so neurological disorders, particularly the neurodegenerative diseases, are becoming more prevalent in society. As per the epidemiological studies, Europe alone suffers 35% of the burden, indicating an alarming rate of disease progression. Further, treatment for these disorders is a challenging area due to the presence of the tightly regulated blood-brain barrier and its unique ability to protect the brain from xenobiotics. Conventional therapeutics, although effective, remain critically below levels of optimum therapeutic efficacy. Hence, methods to overcome the blood-brain barrier are currently a focus of research. Nanotechnological applications are gaining paramount importance in addressing this question, and yielding some promising results. This review addresses the pathophysiology of the more common neurological disorders and novel drug candidates, along with targeted nanoparticle applications for brain delivery.
    International Journal of Nanomedicine 07/2012; 7:3259-78. DOI:10.2147/IJN.S30919 · 4.38 Impact Factor
  • Source
    • "It was disclosed that this can potentially be achieved by molecules targeting by nanoengineering devices. This new method will be effective in treating a variety of illness such as neurological disorders, diabetes, osteoporosis, Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, multiple sclerosis, HIV-1 associated neuro cognitive disorders, cardio vascular disorders, tuberculosis and cancer [14] [15] [16] [17] [18] [19] [20] [21] [22]. NPs such as lipid or polymer can be designed to improve the pharmacological and therapeutical properties of drugs [21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nanotechnology has the potential to offer solutions to these current obstacles in cancer therapies, because of its unique size and large surface-to-volume ratios. Nanoparticles may have properties of self-assembly, stability, specificity, drug............................................................................
    Journal of Cancer Therapy 01/2011; 2(03):325-334. DOI:10.4236/jct.2011.23045
  • [Show abstract] [Hide abstract]
    ABSTRACT: ZnO and TiB<sub>2</sub> are chosen as a thermoelectric (TE) phase and a highly conducting phase, respectively, to construct two-phase ball-shell-type composites. ZnO-coated TiB<sub>2</sub> powders are prepared via sol-gel processing and are then hot pressed in vacuum. The TiB<sub>2</sub> grains in the hot-pressed composite samples are coated with an interfacial layer that consists of Zn<sub>3</sub>B<sub>2</sub>O<sub>6</sub>, TiO<sub>2</sub>, Zn<sub>2</sub>TiO<sub>4</sub>, and ZnB<sub>2</sub>O<sub>4</sub>, rather than ZnO, due to the reactions between ZnO and TiB<sub>2</sub> during sintering. The thermal and electrical conductivity and Seebeck coefficient of the composites were measured in dependence on temperature. The thermoelectric properties of the composite samples are compared to pure ZnO.
    Thermoelectrics, 2002. Proceedings ICT '02. Twenty-First International Conference on; 09/2002
Show more

Similar Publications